Geisbert Thomas W, Bobb Kathryn, Borisevich Viktoriya, Geisbert Joan B, Agans Krystle N, Cross Robert W, Prasad Abhishek N, Fenton Karla A, Yu Hao, Fouts Timothy R, Broder Christopher C, Dimitrov Antony S
Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
NPJ Vaccines. 2021 Feb 8;6(1):23. doi: 10.1038/s41541-021-00284-w.
Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.
尼帕病毒和亨德拉病毒是最近被列入世界卫生组织蓝图重点疾病清单的高致病性蝙蝠传播副粘病毒。自2012年以来，一种完全注册的马抗亨德拉病毒亚单位疫苗一直在澳大利亚使用。基于相同的免疫原，即亨德拉病毒附着糖蛋白胞外结构域，一种用于人类的亚单位疫苗制剂目前正处于I期临床试验阶段。我们报告称，这种人类疫苗制剂的单剂量接种方案可在非人灵长类动物模型中抵御亨德拉病毒或尼帕病毒的致死性攻击。接种低剂量0.1毫克蛋白亚单位后7天，即可开始对孟加拉国尼帕病毒株产生保护作用。我们的数据表明，这种人类疫苗可作为高效的应急疫苗，在疫情爆发时阻止尼帕病的潜在传播。
